Single-shot gene editing for LDL & Vatican calls for AI laws - News (May 26, 2026)

Imagine replacing a lifetime of cholesterol pills with a single treatment—and early data suggests it might cut “bad” cholesterol by more than half. We’ll get to what that could mean, and what still has to be proven. Welcome to The Automated Daily, top news edition. The podcast created by generative AI. I’m TrendTeller, and today is May-26th-2026. Let’s get you caught up—quickly, clearly, and with the context that makes these stories matter.

Single-shot gene editing for LDL

We start with the biggest geopolitical and economic pressure point of the moment: the Strait of Hormuz. Regional officials speaking to the AP say the U.S. is close to a deal with Iran that could end the current war, reopen that critical shipping route, and—most notably—require Tehran to give up its stockpile of highly enriched uranium. The outlines being discussed reportedly include a short window to finalize details, with sanctions relief tied to Iran actually disposing of that material, potentially through dilution or transfer to a third country. Why it matters: when Hormuz is disrupted, global energy prices and shipping insurance don’t just wobble—they lurch. A phased reopening would aim to calm markets, while the nuclear component could reshape the next chapter of nonproliferation diplomacy. But there’s a clear note of caution too: President Donald Trump says he’s urging negotiators not to rush, which signals the political risk of settling for a deal that doesn’t hold up under scrutiny.

Vatican calls for AI laws

Next, a major intervention in the global debate over artificial intelligence—from the Vatican. Pope Leo XIV has released his first encyclical, titled “Magnifica Humanitas,” calling for strong legal regulation of AI, not just voluntary ethics. He argues that when a small number of private companies control massive amounts of data and computing power, society can’t rely on good intentions alone. One of the sharpest points is about warfare: the pope says it’s unacceptable to hand irreversible lethal decisions to machines, and he demands transparency and accountability in any AI-enabled military chain of command. He also warns that AI could displace work at scale, and that economic incentives should not outrank human dignity. This is interesting because it’s not a generic “be careful with tech” message. It’s a direct push for enforceable rules—landing as policymakers worldwide struggle to keep pace with rapidly advancing systems.

U.S.-Iran talks and Hormuz reopening

From AI rules to the hardware race: Huawei is claiming it has a new approach to chip design that could let it reach near cutting-edge performance within several years, despite U.S. sanctions that limit China’s access to the most advanced chipmaking tools. Huawei’s pitch is, essentially, a different route up the mountain: instead of depending mainly on ever-smaller traditional designs, the company says it can stack and arrange circuits in new three-dimensional ways and focus on speeding data movement within the chip. Analysts, though, are urging caution—because making advanced designs work reliably at scale brings real-world challenges like heat, power use, manufacturing yield, and software tooling. The significance is straightforward: if Huawei’s approach holds up, it strengthens China’s push for semiconductor self-reliance and could change the competitive landscape for AI computing—especially as U.S. export controls squeeze what American suppliers can sell into China.

Huawei’s claimed chip design leap

Staying with AI, but shifting to the skies: Boston startup Merlin Labs says it’s testing an AI system designed to be installed on existing aircraft to assist with flying—handling routine tasks, supporting decisions about routing and weather, and communicating with air traffic control. The company says it has completed hundreds of test flights, but passenger use is still years away. Merlin’s message is incrementalism: this is positioned as a safety-focused copilot first, not a near-term replacement for humans. Even so, the military interest is real. Merlin has also landed a sizable U.S. Air Force contract aimed at eventually operating cargo aircraft without pilots onboard. Why this matters: aviation is one of the most regulated safety-critical domains on Earth. If credible automation expands there—even starting with cargo and lower-risk missions—it can ripple across pilot training, airline operations, and the economics of air transport.

AI copilots move toward flights

Now to the health story we teased at the top: Eli Lilly says an experimental one-time gene-editing therapy it picked up through its acquisition of Verve Therapeutics cut LDL “bad” cholesterol by about 62% at a higher dose in an early clinical study. Lilly also says no treatment-related serious adverse events were seen in this initial dataset—an important point after Verve previously dropped an earlier cholesterol-editing program over safety concerns. The big idea here is adherence. Cholesterol-lowering drugs work well, but many people don’t take them consistently for years and years. A one-and-done approach, if it proves safe and durable, could change prevention at a population scale. But the caveat is just as important as the promise: these are early, safety-focused results. The real test is whether the benefits last, and whether larger trials reveal rarer risks.

Cell therapy shows promise for cirrhosis

Another medical development worth watching: researchers in Scotland reported multi-year results for a macrophage-based cell therapy aimed at advanced liver disease and cirrhosis—conditions where transplant is often the only definitive option. In a relatively small trial, patients who received the cell therapy were more likely to be alive years later without needing a transplant compared with those getting standard care, and researchers reported no serious side effects linked to the treatment. The therapy uses a patient’s own immune cells, prepares them, and sends them back in with the goal of reducing scarring and supporting repair. Why it’s interesting: transplant waiting lists are constrained by donor shortages, and late diagnosis is common. Even a therapy that delays or prevents the need for a transplant could have outsized impact for patients and health systems—if larger trials confirm the benefit.

New monitoring and early cancer clues

We’ll close with a rapid round of health research that could influence everyday care. First, cancer and metabolic drugs: new observational data being presented at ASCO suggests people with certain solid tumors who started GLP-1 medicines—drugs best known for diabetes and weight loss—had lower rates of cancer spread compared with similar patients on other diabetes medications. Researchers stress this can’t prove cause and effect, but the signal is consistent enough that it strengthens the case for randomized trials. If confirmed, it would matter for patients juggling diabetes and cancer, and it could open new research into how metabolism and inflammation shape tumor behavior. Second, early detection: UK researchers backed by Cancer Research UK describe a potential urine test for earlier lung cancer detection by looking for protein signals tied to senescent, or “zombie,” cells associated with early tumor development. The hope is a simple screening tool that catches disease before symptoms—when treatment has a much better chance. And third, pregnancy monitoring: a wearable ultrasound patch has been demonstrated as a way to continuously image a fetus for hours and track blood flow in real time. In early trials, the readings matched conventional ultrasound snapshots, and continuous monitoring in at least one high-risk case reportedly helped clinicians act quickly. It’s still a proof-of-concept and not yet a home-ready device, but the direction is clear: longer, more informative monitoring could help spot complications that short, occasional scans might miss.

That’s our top news edition for May-26th-2026. If one theme ties today together, it’s this: big leaps—whether in AI, chips, or medicine—don’t just depend on breakthroughs. They depend on trust, verification, and real-world testing. I’m TrendTeller. Thanks for listening to The Automated Daily. If you want, come back tomorrow and we’ll sort the signal from the noise again.

Single-shot gene editing for LDL & Vatican calls for AI laws - News (May 26, 2026)

Our Sponsors

Today's Top News Topics